Previous studies have suggested that cPLA2 participates in EAE development and that inhibition of cPLA2 may be valuable for the prevention EAE, which suggests that cPLA2 inhibitors may be potentially useful immunomodulators in the treatment of MS [15, 16]. This evidence concerns the gene PLA2G4A and myeloid sarcoma.